Laurie Tota
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Pharmacological Effects and Assays, Adipose Tissue and Metabolism, Diabetes Treatment and Management, Neuropeptides and Animal Physiology
Most-Cited Works
- → Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice(2009)405 cited
- → Human β3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides(2000)199 cited
- Potent and selective human beta(3)-adrenergic receptor antagonists.(1999)
- → A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects(2004)109 cited
- → Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant.(1996)90 cited
- → Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes(2012)86 cited
- → Potent and Selective Human β3-Adrenergic Receptor Antagonists(1999)64 cited
- → Potent, selective human β3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore(1999)64 cited
- → Discovery of a Potent, Orally Bioavailable β3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide(2000)63 cited
- → Phytosphingosine 1-phosphate: a high affinity ligand for the S1P4/Edg-6 receptor(2002)59 cited